tiprankstipranks
Sage Therapeutics reports results from Phase 2 DIMENSION Study
PremiumThe FlySage Therapeutics reports results from Phase 2 DIMENSION Study
2d ago
Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
Premium
The Fly
Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
16d ago
Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley
Premium
The Fly
Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley
18d ago
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
PremiumThe FlySage Therapeutics price target lowered to $26 from $52 at Piper Sandler
23d ago
Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright
Premium
The Fly
Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright
23d ago
Sage Therapeutics Reports Q3 Growth and Strategic Focus
Premium
Company Announcements
Sage Therapeutics Reports Q3 Growth and Strategic Focus
23d ago
Class Action Lawsuit Against Sage Therapeutics (NASDAQ:SAGE)
PremiumMarket NewsClass Action Lawsuit Against Sage Therapeutics (NASDAQ:SAGE)
1M ago
Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
Premium
The Fly
Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
1M ago
Sage Therapeutics reinstated with a Market Perform at Raymond James
Premium
The Fly
Sage Therapeutics reinstated with a Market Perform at Raymond James
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100